Literature DB >> 1534853

Protection against Friend retrovirus-induced leukemia by recombinant vaccinia viruses expressing the gag gene.

M Miyazawa1, J Nishio, B Chesebro.   

Abstract

High sequence variability in the envelope gene of human immunodeficiency virus has provoked interest in nonenvelope antigens as potential immunogens against retrovirus infection. However, the role of core protein antigens encoded by the gag gene in protective immunity against retroviruses is unclear. By using recombinant vaccinia viruses expressing the Friend murine leukemia helper virus (F-MuLV) gag gene, we could prime CD4+ T-helper cells and protectively immunize susceptible strains of mice against Friend retrovirus infection. Recovery from leukemic splenomegaly developed more slowly after immunization with vaccinia virus-F-MuLV gag than with vaccinia virus-F-MuLV env; however, genetic nonresponders to the envelope protein could be partially protected with Gag vaccines. Class switching of F-MuLV-neutralizing antibodies from immunoglobulin M to immunoglobulin G after challenge with Friend virus complex was facilitated in mice immunized with the Gag antigen. Sequential deletion of the gag gene revealed that the major protective epitope was located on the N-terminal hydrophobic protein p15.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1534853      PMCID: PMC241259     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  47 in total

1.  IgG or IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing Lyt 2 antigen block T cell-mediated cytolysis in the absence of complement.

Authors:  M Sarmiento; A L Glasebrook; F W Fitch
Journal:  J Immunol       Date:  1980-12       Impact factor: 5.422

2.  Cytotoxic T lymphocyte recognition of gp70 on Friend virus-induced erythroleukemia cell clones.

Authors:  J K Collins; W J Britt; B Chesebro
Journal:  J Immunol       Date:  1980-09       Impact factor: 5.422

3.  Immune response and epitope mapping of a candidate HIV-1 p17 vaccine HGP30.

Authors:  C A Boucher; W J Krone; J Goudsmit; R H Meloen; P H Naylor; A L Goldstein; D K Sun; P S Sarin
Journal:  J Clin Lab Anal       Date:  1990       Impact factor: 2.352

4.  HGP-30, a synthetic analogue of human immunodeficiency virus (HIV) p17, is a target for cytotoxic lymphocytes in HIV-infected individuals.

Authors:  A Achour; O Picard; D Zagury; P S Sarin; R C Gallo; P H Naylor; A L Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

5.  Characterization of monoclonal antibodies against the human immunodeficiency virus matrix protein, p17gag: identification of epitopes exposed at the surfaces of infected cells.

Authors:  F Shang; H Huang; K Revesz; H C Chen; R Herz; A Pinter
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

6.  General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes.

Authors:  M Mackett; G L Smith; B Moss
Journal:  J Virol       Date:  1984-03       Impact factor: 5.103

7.  Oligonucleotide sequence signaling transcriptional termination of vaccinia virus early genes.

Authors:  L Yuen; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1987-09       Impact factor: 11.205

8.  Construction and characterization of an infectious vaccinia virus recombinant that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters.

Authors:  G L Smith; B R Murphy; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1983-12       Impact factor: 11.205

9.  HIV-specific cytotoxic T lymphocytes in seropositive individuals.

Authors:  B D Walker; S Chakrabarti; B Moss; T J Paradis; T Flynn; A G Durno; R S Blumberg; J C Kaplan; M S Hirsch; R T Schooley
Journal:  Nature       Date:  1987 Jul 23-29       Impact factor: 49.962

10.  The effect of histocompatibility-2 type on response to friend leukemia virus in mice.

Authors:  F Lilly
Journal:  J Exp Med       Date:  1968-03-01       Impact factor: 14.307

View more
  33 in total

1.  Vaccination with an adenoviral vector that encodes and displays a retroviral antigen induces improved neutralizing antibody and CD4+ T-cell responses and confers enhanced protection.

Authors:  Wibke Bayer; Matthias Tenbusch; Ruth Lietz; Lena Johrden; Simone Schimmer; Klaus Uberla; Ulf Dittmer; Oliver Wildner
Journal:  J Virol       Date:  2009-12-09       Impact factor: 5.103

Review 2.  Immunity to retroviral infection: the Friend virus model.

Authors:  K J Hasenkrug; B Chesebro
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

3.  Modification of one epitope-flanking amino acid allows for the induction of friend retrovirus-specific CD8+ T cells by Adenovirus-based immunization.

Authors:  Philipp Gödel; Sonja Windmann; Kirsten K Dietze; Ulf Dittmer; Wibke Bayer
Journal:  J Virol       Date:  2012-08-29       Impact factor: 5.103

4.  Role of natural killer cells in resistance against friend retrovirus-induced leukemia.

Authors:  N Iwanami; A Niwa; Y Yasutomi; N Tabata; M Miyazawa
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

Review 5.  Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety.

Authors:  B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

6.  Multiplicity of virus-encoded helper T-cell epitopes expressed on FBL-3 tumor cells.

Authors:  M Iwashiro; T Kondo; T Shimizu; H Yamagishi; K Takahashi; Y Matsubayashi; T Masuda; A Otaka; N Fujii; A Ishimoto
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

7.  Contrasting effects from a single major histocompatibility complex class II molecule (H-2E) in recovery from Friend virus leukemia.

Authors:  L L Perry; M Miyazawa; K Hasenkrug; K Wehrly; C S David; B Chesebro
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

8.  Analysis of two monoclonal antibodies reactive with envelope proteins of murine retroviruses: one pan specific antibody and one specific for Moloney leukemia virus.

Authors:  Leonard H Evans; Stefano Boi; Frank Malik; Kathy Wehrly; Karin E Peterson; Bruce Chesebro
Journal:  J Virol Methods       Date:  2014-02-17       Impact factor: 2.014

9.  Dissecting the immune response to moloney murine sarcoma/leukemia virus-induced tumors by means of a DNA vaccination approach.

Authors:  G Milan; A Zambon; M Cavinato; P Zanovello; A Rosato; D Collavo
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

Review 10.  Humoral immunity in the Friend retrovirus infection model.

Authors:  Kalani Halemano; Michael S Harper; Kejun Guo; Sam X Li; Karl J Heilman; Bradley S Barrett; Mario L Santiago
Journal:  Immunol Res       Date:  2013-03       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.